Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer

Status: Recruiting
Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer
NCT ID: NCT01750918 (View complete trial on
DFCI Protocol ID: 13-074


This is an open-label, three-part Phase 1/2 study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of trametinib (GSK1120212) and dabrafenib (GSK2118436) when administered in combination with the anti-EGFR antibody panitumumab in subjects with BRAF-mutation V600E or V600K positive colorectal cancer (CRC). Part 1 of the study will consist of dose-escalation cohorts Part 2 of the study will consist of expansion cohorts to investigate safety and clinical activity, and Part 3 of the study will be a randomized Phase II study comparing both the dabrafenib/panitumumab and dabrafenib/trametinib/panitumumab combinations to a chemotherapy comparator with respect to safety and clinical activity.


Conducting Institutions:
Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital

Overall PI:
Ryan Corcoran, M,D, Ph.D, Massachusetts General Hospital

Site-responsible Investigators:
Jeffrey Meyerhardt, MD, Dana-Farber Cancer Institute

Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Gastrointestinal Research Line, 617-632-5960

Eligibility Criteria

INCLUSION CRITERIA - Written informed consent provided. - At least 18 years of age or older. - Able to swallow and retain oral medication. - No clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels. - Confirmed diagnosis of advanced or metastatic BRAF V600E or V600K mutation positive colorectal cancer (CRC). - Archival tissue is required; if archival tissue is not available or found to not contain tumor tissue, a fresh biopsy is required. - Measurable disease per RECIST version 1.1. - Performance Status Score of 0 or 1 according to the Eastern Cooperative Oncology Group scale. - Men must have either: had a prior vasectomy, or agree to use one of the contraception methods listed in the protocol from the time of the first dose of study drug(s) and until 6 months after the last dose of panitumumab, or 16 weeks following the last dose of dabrafenib or trametinib, based on the life cycle of sperm. - Female subjects are eligible if: Non-childbearing potential defined as: pre-menopausal females with a documented tubal ligation or hysterectomy; or post-menopausal female defined as 12 months of spontaneous amenorrhea to be verified with a follicle-stimulating hormone (FSH) level >40MIU/mL and estradiol level <40pg/mL. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in the protocol if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. Child-bearing potential and agrees to use one of the contraceptive methods listed in the protocol for an appropriate period of time as determined by the product label and applicable IBs) prior to the start of dosing to sufficiently minimize risk of pregnancy at that point. - Female subjects must agree to use contraception from the time of the first dose of study drug(s) until 60 days after the last dose of any study drug. Note: oral contraceptives are not reliable due to potential drug-drug interactions. - Women of childbearing potential must have had a negative serum pregnancy test within 7 days prior to the first dose of study drug(s). - Adequate organ system functions, including: absolute neutrophil count greater than or equal to 1.2X10^9/L, hemoglobin greater than or equal to 9 g/dL or 5.6 mmol/L, platelets greater than or equal to75 × 10^9/L, Prothrombin Time / International Normalized Ratio (PT/INR) and Partial Thromboplastin Time (PTT) less than or equal to 1.5Xupper limit of normal (ULN) serum magnesium greater than or equal to the lower limit of normal (LLN) albumin greater than or equal to 2.5 g/dL or 25 g/L, total bilirubin less than or equal to 1.5XULN, and AST and ALT less than or equal to 2.5XULN creatinine less than or equal to 1.5XULN or calculated creatinine clearance greater than or equal to 50mL/min left ventricular ejection fraction (LVEF) greater than or equal to the LLN by echocardiography (ECHO) or multigated acquisition scan (MUGA). EXCLUSION CRITERIA - History of prior malignancy, other than colorectal cancer. - Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures. - Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator's assessment). - History of sensitivity to heparin or heparin-induced thrombocytopenia. - Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy or biologic therapy), as described in the protocol. - Prior exposure to BRAF or MEK inhibitors. - Prior exposure to EGFR inhibitors, including anti-EGFR antibodies or EGFR (for patients enrolling in Part 2 ONLY) - Known presence of KRAS-mutation based on previous KRAS-testing. - Received an investigational or approved anti-cancer drug within 4 weeks, or within 5 half-lives (whichever is shorter) of the first dose of study drug(s). At least 14 days must have passed between the last dose of prior investigational agent and the first dose of study drug(s). - Current use of a prohibited medication or requirement to dose with any of these medications during treatment with study drug(s). - Known human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection. Subjects who have evidence of clearance of Hepatitis B or Hepatitis C infection can be enrolled with approval of the GSK Medical Monitor. - Current use of therapeutic warfarin. Therapeutic dosing of warfarin is defined as resulting in an INR greater than 1.3. Low molecular weight heparin (LMWH) is permitted provided that the subject's PT and PTT meet entry criteria. Subjects requiring therapeutic levels of LMWH must receive approval from GSK Medical Monitor and must be monitored appropriately as clinically indicated. - Any major surgery, radiotherapy or immunotherapy within the 4 weeks prior to first dose of study drug(s). Limited radiotherapy with in the 2 weeks prior to first dose of study drug(s). - Chemotherapy regimens with delayed toxicity within the 3 weeks prior to first dose of study drug(s). Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within 2 weeks prior to first dose of study drug(s). - Unresolved toxicity greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE; version 4) Grade 1 from previous anti-cancer therapy, with the exception of Grade 2 alopecia, Grade 2 neuropathy, or laboratory values that are allowed per inclusion criteria. - History of retinal vein occlusion (RVO) or central serous retinopathy (CSR), predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes). - Visible retinal pathology as assessed by ophthalmic examination that is considered a risk for RVO or CSR, such as: Evidence of new optic disc cupping. Evidence of new visual field defects. Intraocular pressure greater than 21mm Hg as measured by tonography. - Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of drugs. Previous colectomy is acceptable. - Subjects with brain metastases are excluded, unless: All known lesions must be previously treated with surgery or stereotactic radiosurgery, and Brain lesion(s), if present, must be confirmed stable (i.e., no increase in lesion size) for greater than or equal to 90 days prior to first dose of study drug(s). This must be documented with two consecutive MRI or CT scans using contrast, and Asymptomatic with no corticosteroids requirement for greater than or equal to 30 days prior to first dose of study drug(s), and No enzyme-inducing anticonvulsants for greater than or equal to 14 days prior to first dose of study drug(s). In addition, for subjects that had brain metastases but currently have no evidence of disease (NED), NED for greater than or equal to 12 weeks is required and must be confirmed by two consecutive MRI or CT scans (using contrast) separated by greater than or equal to 6 weeks, prior to randomization. Enrollment of a subject with brain metastases who meet the above criteria requires approval of a GSK Medical Monitor. - Psychological, familial, sociological or geographical conditions that do not permit compliance with the protocol. - History or evidence of cardiovascular risk including any of the following: LVEF less than LLN A QT interval corrected for heart rate using the Bazett's formula (QTcB) greater than or equal to 480 msec; History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for greater than 30 days prior to randomization are eligible. History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization. History or evidence of current greater than or equal to Class II congestive heart failure as defined by New York Heart Association (NYHA). Treatment refractory hypertension defined as a blood pressure of systolic greater than 140 mmHg and/or diastolic greater than 90 mm Hg which cannot be controlled by anti-hypertensive therapy; Subjects with intra-cardiac defibrillators or permanent pacemakers; Known cardiac metastases; - Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event less than or equal to 30 days before randomization. If on anticoagulation, subject must be on stable therapeutic dose prior to randomization. - Subjects with a history of pneumonitis or interstitial lung disease (ILD). - Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug(s) or their excipients. - Pregnant or lactating female. - Unwillingness or inability to follow the procedures outlined in the protocol. - Uncontrolled diabetes or other medical condition that may interfere with assessment of toxicity.
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.


Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters